TSX runs higher on rate cut expectations
Today, Brera Holdings PLC, a company specializing in amusement and recreation services, announced the scheduling of its 2024 annual general meeting (AGM) for shareholders. The meeting is set to occur on March 28, 2025, at 2:00 p.m. GMT (10:00 a.m. EDT), and will be accessible online. The announcement comes as the company’s stock trades at $5.07, having experienced significant volatility with an 86% decline over the past year. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value assessment.
The Dublin-based public limited company, which operates under the organization name 07 Trade & Services, disclosed the meeting details through a notice made available to its shareholders. In compliance with the Securities Exchange Act of 1934, the notice and proxy statement have been filed with the United States Securities and Exchange Commission.
Shareholders of record will be able to join the AGM via a designated online platform. The company has provided a proxy card form for those unable to attend, allowing them to vote on corporate matters by proxy.
The announcement did not elaborate on the specific agenda items to be discussed during the AGM. However, such meetings typically cover annual financial statements, the election of board members, and other key corporate governance matters.
The notice of the AGM and accompanying documents, including the proxy statement, are integral to ensuring shareholders are informed and can exercise their voting rights on company affairs.
Brera Holdings PLC, previously known as Brera Holdings Ltd, underwent a name change on July 26, 2022. The company’s corporate headquarters are located at Connaught House, 5th Floor, One Burlington (NYSE:BURL) Road, Dublin 4, D04 C5Y6, Ireland. With a market capitalization of $10.47 million and revenue of $920,000 in the last twelve months, the company faces significant operational challenges, as highlighted by its negative EBITDA of -$21.59 million. Detailed financial analysis and valuation metrics are available through InvestingPro.
This news article is based on a press release statement.
In other recent news, Mainz Biomed has regained compliance with Nasdaq’s stockholders’ equity requirement. The company received formal notification confirming it meets the necessary standards for continued listing on the Nasdaq Capital Market. Previously, Mainz Biomed had also met Nasdaq’s minimum bid price requirement. These developments ensure that Mainz Biomed remains fully compliant with all Nasdaq continued listing standards. The company focuses on early cancer detection diagnostics and is currently conducting an FDA clinical study for its ColoAlert® test, which is available in Europe and the United Arab Emirates. Additionally, Mainz Biomed is developing PancAlert, a screening test for early-stage pancreatic cancer. The company emphasizes its commitment to maintaining the standards required for listing on a major stock exchange. This news is based on a press release from the company, highlighting its dedication to meeting financial, liquidity, and corporate governance criteria.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.